(2R)-4-[(8R)-8-methyl-2-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl]-4-oxo-1-(2,4,5-trifluorophenyl)butan-2-amine

This compound is a synthetic small molecule belonging to the class of beta amino acids and derivatives. It has been studied as an experimental drug and is known by its DrugBank identifier DB07081. Structurally, it features a triazolopyrazine core with multiple trifluoromethyl substitutions. The compound has been identified as an inhibitor of dipeptidyl peptidase 4 (DPP-IV), a serine protease involved in glucose metabolism and immune regulation. DPP-IV inhibitors are commonly explored for their potential in treating type 2 diabetes mellitus by prolonging the activity of incretin hormones that stimulate insulin secretion[1][7]. This molecule has also been co-crystallized with group X secretory phospholipase A2 (sPLA2-X), suggesting possible research interest in inflammation or related pathways[7]. However, there is no evidence that this compound has advanced beyond preclinical or early experimental stages.